middle.news
Alterity Therapeutics Unveils Promising Phase 2 Data for ATH434 in Multiple System Atrophy
9:20am on Thursday 30th of January, 2025 AEDT
•
Biotechnology
Read Story
Alterity Therapeutics Unveils Promising Phase 2 Data for ATH434 in Multiple System Atrophy
9:20am on Thursday 30th of January, 2025 AEDT
Key Points
ATH434 demonstrated up to 48% slowing of clinical progression on UMSARS scale
Significant reduction of iron accumulation in key brain regions confirmed by MRI
Favorable safety profile with no serious adverse events related to ATH434
Positive trends observed in motor function and brain volume preservation
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Alterity Therapeutics (ASX:ATH)
OPEN ARTICLE